EUCTR2008-004828-23-GB进行中（未招募）不适用
A Cancer Research UK Phase II Trial to compare [11C]choline and [18F]choline each given as a single administration via intravenous injection for imaging patients with metastatic prostate cancer - Phase II trial comparing [11C]choline and [18F]choline for the imaging of metastatic prostate cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Histologically proven prostate cancer
- •2. At least 4 new metastatic bone lesions, as identified by conventional imaging with bone scintigraphy
- •3. Either:
- •a) Treatment naive for prostate cancer
- •b) Castration refractory prostate cancer [castrate will be defined as a testosterone level of <50 ng/dL (<2 nM)] with progressive disease (PD). PD will be defined by fulfilment of at least one of the following criteria:
- •PSA progression defined as a rising PSA according to Prostate Cancer Working Group 2 (PCWG2) criteria
- •Soft tissue disease progression defined by RECIST 1.1 (Eisenhauer E.A., et al., 2009)
- •Bone disease progression defined by PCWG2 with two or more lesions on bone scan
- •These patients will either have previously known bone metastases on bone scintigraphy and are now progressing on LHRHa with or without maximum androgen blockade, or, will not previously have had known bone metastases
- •4. Life expectancy of at least 12 weeks
- •5. World Health Organisation (WHO) performance status of 0, 1, or 2
- •6. Haematological and biochemical indices within the ranges shown below performed within 24 hours prior to administration on Day 1 (Day -1 to Day 1).
- •Laboratory TestValue required
- •Haemoglobin (Hb) =9.0 g/dL
- •Platelet count =100 x 10(9)/L
- •Serum bilirubin =1.5 x upper limit of normal (ULN)
- •ALT and AST =2.5 x ULN (unless raised due to tumour when =5 x ULN is permissible)
- •7. 18 years or over
- •8. Written (signed and dated) informed consent and able to comply with study assessments and follow-up
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. For treatment naive patients any prior radiotherapy, hormone therapy, chemotherapy, endocrine therapy, or immunotherapy, for treatment of prostate cancer
- •For castration refractory patients any prior radiotherapy, chemotherapy, or immunotherapy for treatment of prostate cancer
- •2. Patients with partners of child-bearing potential (unless they agree to take measures not to father children by using two forms of medically approved contraception during the trial)
- •3. Patients with the following conditions which would prevent compliance with the scanning protocol:
- •- Diabetes
- •- High levels of pain / discomfort
- •- Urinary incontinence
- •4. Major thoracic and/or abdominal surgery from which the patient has not yet recovered.
- •5. History of recent significant cardiac arrhythmia
- •6. Concurrent congestive heart failure or prior history of class III/IV cardiac disease (NYHA)
- •7. Any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial
- •8. Participation or planned participation in any other interventional clinical trial, whilst taking part in this trial. Participation in an observational trial would be acceptable.
研究者
相似试验
进行中（未招募）
1 期
An early trial of a new type of three-dimensional imaging called [124I]mIBG PET/CT in children with a type of cancer called neuroblastoma.EUCTR2012-002029-31-GBCancer Research UK33
进行中（未招募）
1 期
A Phase I/II trial of UCB4594 in participants with advanced cancerAdvanced solid tumoursCancerISRCTN26628699Cancer Research UK167
已完成
1 期
A Phase I/IIa trial of BT1718 in patients with advanced solid tumours.CancerISRCTN11160449Cancer Research UK66
进行中（未招募）
不适用
A trial looking at a new drug called AG-014699 for breast and ovarian cancer in people with gene faultsadvanced or metastatic breast or ovarian carcinoma (proven carrier of a mutation in BRCA1 or 2 gene)EUCTR2006-002348-27-GBCancer Research UK
进行中（未招募）
1 期
Phase I/II study of abiraterone in ER or AR positive breast cancerEUCTR2007-003240-30-GBCancer Research UK77